PURETECH HEALTH PLC - AMERICAN DEPOSITARY SHARES
PURETECH HEALTH PLC - AMERICAN DEPOSITARY SHARES
Depository Receipt · US7462371060 · PRTC (XNAS)
Overview
18,31 USD
-3,63 % -0,69 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
09.06.2025 19:56

Current Prices from PURETECH HEALTH PLC - AMERICAN DEPOSITARY SHARES

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
PRTC
USD
09.06.2025 19:56
18,31 USD
19,00 USD
-3,63 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % -2,81 % 9,11 % 2,01 % -18,11 % -38,80 % -52,44 %

Company Profile for PURETECH HEALTH PLC - AMERICAN DEPOSITARY SHARES Depository Receipt

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Company Data

Name PURETECH HEALTH PLC - AMERICAN DEPOSITARY SHARES
Company PureTech Health plc
Symbol PRTC
Website https://www.puretechhealth.com
Primary Exchange XNAS NASDAQ
ISIN US7462371060
Asset Class Depository Receipt
Sector Healthcare
Industry Biotechnology
CEO Dr. Bharatt M. Chowrira J.D., Ph.D.
Market Capitalization 402 Mio
Country United States of America
Currency USD
Employees 0,1 T
Address 6 Tide Street, 02210 Boston
IPO Date 2020-11-16

Ticker Symbols

Name Symbol
Frankfurt 0VQ0.F
NASDAQ PRTC

More Shares

Investors who PURETECH HEALTH PLC - AMERICAN DEPOSITARY SHARES hold also have the following shares in their portfolio:
LUMINOR BANK 23/27FLR MTN
LUMINOR BANK 23/27FLR MTN Bond
S.DIEG.G.+E. 23/28
S.DIEG.G.+E. 23/28 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025